与粉样蛋白相关的疾病的近距离诱导药理学
Andrea Bertran-Mostazo1,2, Gabrielė Putriūtė1, Irene Álvarez-Berbel1
1Department of Pharmacy and Pharmaceutical Technology and Physical-Chemistry, School of Pharmacy, University of Barcelona, 08028 Barcelona, Spain.
Cells
|March 13, 2024
概括
接近诱导药理学 (PIP) 为阿尔茨海默氏症等粉样蛋白相关疾病提供了一种新的治疗策略. 这种方法使用向分子来分解有害蛋白质并减少斑块的积累,为有效的痴呆症治疗铺平了道路.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 粉样蛋白相关的疾病,包括阿尔茨海默病,以病原蛋白质的积累和大脑中的斑块形成为特征.
- 目前治疗痴呆症的方法往往缺乏特异性,并且有效性有限.
- 制定有针对性的治疗策略对于对抗神经退行性疾病至关重要.
研究的目的:
- 引入和探索近距离诱导药理学 (PIP) 的潜力,作为粉样蛋白相关疾病的新疗法.
- 突出PIP可以准和降解粉样蛋白质的机制.
- 讨论PIP在向β-粉样蛋白等蛋白质中的特异性.
主要方法:
- 这种方法涉及到小分子的战略设计和应用.
- 这些分子被设计为在特定的粉样蛋白相关蛋白质附近定位.
- 靠近可以诱导药理效应来改变蛋白质结构和功能.
主要成果:
- PIP显示了分解病原性粉样蛋白质的能力.
- 它有效地减少了粉样质斑块的积累,这是阿尔茨海默氏症等疾病的标志.
- 该模式提供了高特异性,针对特定的粉样蛋白,如β-粉样蛋白.
结论:
- 近距离诱导药理学为治疗阿尔茨海默病和其他痴呆症提供了一种有希望的,尖端的方法.
- 它的特异性允许更有针对性,可能更有效的治疗干预措施.
- 继续研究和优化PIP具有显著的潜力,可以改善神经退行性疾病患者的治疗结果.
相关概念视频
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Alzheimer's Disease: Treatment
186
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
186
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.2K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.2K
Alzheimer's Disease: Overview
475
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
475
Ligand-gated Ion Channels
12.4K
Ligand-gated ion channels are transmembrane proteins with a channel for ions to pass through and a binding site for a ligand. The channel opens only when a ligand attaches to the binding site.
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
12.4K
Drug-Receptor Interaction: Agonist
2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K


